Results 31 to 40 of about 11,205 (172)

Predictors of outcome in idiopathic rapidly progressive glomerulonephritis (IRPGN)

BMC Nephrology, 2006
Background Small vessel vasculitides are known to follow a devastating course towards end-stage renal disease, unless treated with immunosuppressive regiments.
Leontsini Maria, Kokolina Elizabeth, Papayianni Ekaterini, Gionanlis Lazaros, Alexopoulos Efstathios, Memmos Dimitrios   +5 more
doaj   +1 more source

Secondary syphilis associated crescentic glomerulonephritis: A case report

Human Pathology Reports, 2021
Introduction: Syphilis is a sexually transmitted disease caused by the bacterium Treponema Pallidum and has a diverse clinical presentation, including nephropathies, the most common of which is membranous nephropathy. Crescentic glomerulonephritis is not
Marcelo Santos Sampaio, Grigoriy Alexander Shekhtman, Mandana Rastegar, Richard Michael Treger, Glenn Tetsu Nagami, Jonathan Eric Zuckerman   +5 more
doaj   +1 more source

Voclosporin‐induced gingival enlargement: A case report

Clinical Advances in Periodontics, EarlyView.
Abstract Background Drug‐influenced gingival enlargement (DIGE) is a recognized adverse effect of certain medications, particularly immunosuppressants like cyclosporin and tacrolimus. However, there have been no documented cases of DIGE associated with voclosporin, a newer calcineurin inhibitor used primarily to treat lupus nephritis.
Francesca Racca, Jessica M. Greco, Dimitris N. Tatakis   +2 more
wiley   +1 more source

Etiology and outcome of rapidly progressive glomerulonephritis in children

Journal of Pediatric Critical Care, 2019
Introduction: Rapidly progressive glomerulonephritis( RPGN) in children is an uncommon entity. There is paucity of studies on this. It is diagnosed with clinical features of oliguria, hematuria and renal failure in weeks.
Alok Kumar, Dorchhom Khrime, Nitin Kumar Bansal, Utkarsh Sharma   +3 more
doaj   +1 more source

AL Amyloidosis Presenting With Crescentic Glomerulonephritis

Kidney Medicine, 2021
Kidney amyloidosis typically presents with nephrotic-range proteinuria. Rare cases of crescentic glomerulonephritis have been reported in patients with kidney amyloidosis but most cases were in the setting of patients with AA amyloidosis from long ...
Ann A. Wang, Yashpal S. Kanwar, Vikram Aggarwal, Anand Srivastava   +3 more
doaj   +1 more source

Disseminated Histoplasmosis: An Unusual Finding at ROSE

Diagnostic Cytopathology, EarlyView.
ABSTRACT We describe an unusual case in which disseminated histoplasmosis was suspected at the time of of rapid on‐site assessment (ROSE) performed during endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA). The patient was a renal transplant recipient with fever, mild anemia, bilateral lung infiltrates and mediastinal ...
Erika E. Doxtader, Jona Banzon, Sanjay Mukhopadhyay   +2 more
wiley   +1 more source

Engineered extracellular vesicles for precision renal therapy: Bioengineering strategies and clinical translation

Interdisciplinary Medicine, EarlyView.
Engineered extracellular vesicles (EVs) offer a versatile platform for kidney‐targeted therapy. This review summarizes bioengineering strategies, including cargo loading, surface modification, biomimetic fabrication, and biomaterial integration. We highlight translational challenges and propose future solutions to accelerate the clinical application of
Linru Shi, Bei Li, Wanzhu Liu, Haifeng Wu, Wenrong Xu, Cheng Ji, Hui Qian   +6 more
wiley   +1 more source

Impact of barometric pressure on blood pressure during dialysis: Introducing intradialytic time‐averaged cumulative systolic blood pressure (TACsBP‐inD) as a new metric

Therapeutic Apheresis and Dialysis, Volume 29, Issue 3, Page 525-534, June 2025.
Abstract Background Blood pressure is a crucial risk factor for hemodialysis patients, but the specific impact of weather factors, particularly barometric pressure, on blood pressure remains unclear. This study aims to examine the relationship between barometric pressure and blood pressure in hemodialysis patients. Methods We conducted a single‐center,
Kosaku Iwatsubo, Shouichi Fujimoto, Michikazu Nakai   +2 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Rapid improvement of renal microcirculatory homeostasis by liraglutide following diabetes induction

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Renal microvascular dysfunction is a central driver of diabetic kidney disease, yet the potential for rapid therapeutic reversal remains obscure. We investigated the effect of short‐term liraglutide on early changes in the renal microcirculation post‐induction of diabetes.
Yuan Li, Weiqi Liu, Yingyu Wang, Bing Wang, Xiang Xu, Bingwei Li, Mingming Liu, Xu Zhang, Ruijuan Xiu   +8 more
wiley   +1 more source